The chronotropic effect of acetylcholine in the presence of vecuronium and atracurium A study in the isolated perfused rabbit heart

The bradycardia produced by 1 microgram acetylcholine in the isolated perfused rabbit heart, in the presence of vecuronium and atracurium, was studied and compared with control. Vecuronium at a concentration of 2.5 micrograms/litre and atracurium 6 micrograms/litre did not enhance the negative chronotropic effect of acetylcholine. Atracurium produced a statistically significant inhibition of the negative chronotropic effect of acetylcholine.     

MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients

Little is known about biological predictors of treatment response in panic disorder (PD). In the present study heart rate, blood pressure, plasma cortisol and plasma MHPG were investigated at baseline in a sample of 44 PD patients as possible predictors for nonresponse to treatment. We used a strict definition of nonresponse to find patients who did not respond at all after 12 weeks of treatment with brofaromine or fluvoxamine. Patients were considered nonresponders when they fulfilled two criteria: they did not show a 50% reduction of agoraphobic avoidance and they still experienced panic attacks at endpoint. The variables that differed significantly between the groups were used to predict nonresponse to drug therapy. Using this strict definition of nonresponse, 15 patients (32.6%) were considered nonresponders. These patients were characterised by a higher plasma MHPG concentration and a higher heart rate at baseline. These variables were subsequently used to predict nonresponse.     

低温保存同种心脏瓣膜活性及临床应用的研究

取正常成人心脏瓣膜３６个，置于低浓度广谱抗生素的营养液（ＲＰ－ＭＩ１６４０细胞培养液）中灭菌４８ｈ，－８０℃冰箱初冻，置于液氮中长期保存。灭菌前后瓣膜细菌培养阴性率分别为９４．３％和１００％，解冻后经光镜、电镜检查证实瓣组织细胞结构正常，组织培养葡萄糖消耗率测定示瓣组织存活良好。临床同种心脏瓣膜原位移植３例，随访６～３０个月，瓣功能良好     

β受体阻滞在心血管疾病中的临床应用研究进展

依据国内外的临床研究和循证医学分析,对β受体阻滞剂在心血管疾病方面的合理应用以及适应证,给药方法进行循证性举证,提示β受体阻滞剂可明显改善心血管疾病的临床预后,除非有禁忌证及不能酎受者,β受体阻滞剂应作为心血管疾病的常规治疗病物广泛应用于心血管疾病。     

山莨菪碱对梗阻性黄疸心脏的保护作用

目的 观察梗阻性黄疸时山莨菪碱对心脏的保护作用。方法将30只成年Wistar大鼠随机分为假手术组和梗阻性黄疸模型组;模型组包括山莨菪碱治疗组,生理盐水对照组。分别于术后第14、28天测定各组血浆内毒素含量,观察心肌病理、酶组织化学和心率改变及山莨菪碱治疗后的变化。结果生理盐水对照组血浆内毒素水平明显升高,心肌出现变性、局灶坏死、线粒体破损等病理改变,心肌组织琥珀酸脱氢酶、腺苷三磷酸酶活性明显降低(P<0.05),而酸性磷酸酶活性明显增强(P<0.05),心率明显减缓(P<0.05),山莨菪碱治疗组则以上情况均有明显改善(P>0.05)。结论 山莨菪碱对梗阻性黄疸时心脏有保护作用。     

超声心动图对主动脉窦瘤破裂合并畸形的诊断价值

目的 评价超声心动图对主动脉窦瘤破裂合并畸形的诊断价值，探讨漏诊原因，以提高诊断阳性率。方法 回顾分析23例主动脉窦瘤破裂合并畸形的超声心动图特征，比较超声心动图与手术诊断结果。结果 超声心动图对主动脉窦瘤破裂合并畸形诊断符合率为86．95％（20／23），漏诊率为13．04％（3／23）。结论 超声心动图检查对诊断主动脉窦瘤破裂合并畸形有重要的临床价值，全面掌握超声知识，仔细认真地检查可避免漏诊。     

血小板活化状态在先天性心脏病中的作用

目的：研究血小板的活化状态在先天性心脏病中的作用。方法：采用流式细胞术测定P选择素的表达作为血小板活化的特异性指标，患者分为非紫绀组32例、紫绀组9例、健康对照组12例．研究先天性心脏病患者血小板活化功能的变化。结果：与健康对照组相比，非紫绀组和紫绀组先天性心脏病患者P选择素的表达均明显升高，紫绀组尤为显著。结论：先天性心脏病患者存在血小板的活化状态，紫绀型先天性心脏病更明显，这可能是引起这些患者止血功能异常的原因之一。     

应用抗凝剂的心脏瓣膜置换患者接受胆道手术的术前处理

目的总结瓣膜置换患者行胆道手术的术前用药方法。方法对38例瓣膜置换后在服用华法令过程中因胆道疾病需行择期手术治疗的患者随机分为2组,肝功能正常组(A组)23例、肝功能不正常组(B组)15例均于术前3d停服华法令,B组术前12h肌注VitK110mg。术前无应用华法令历史的患者115例做为对照组。结果38例患者停药2d后A组血浆凝血酶原时间与对照组差异无显著意义,B组于术前12h肌注VitK110mg后,血浆凝血酶原时间与对照组相比差异也无显著性意义。结论瓣膜置换患者在抗凝期间行胆道手术,只要准备充分,围手术期是安全的。     

An overview of new pharmacological treatments for cerebrovascular dysfunction after experimental subarachnoid hemorrhage

Cerebral vasospasm and the resulting cerebral ischemia occurring after subarachnoid hemorrhage (SAH) are still responsible for the considerable morbidity and mortality in patients affected by cerebral aneurysms. Mechanisms contributing to the development of vasospasm, abnormal reactivity of cerebral arteries and cerebral ischemia after SAH have been intensively investigated in recent years. It has been suggested that the pathogenesis of vasospasm is related to a number of pathological processes, including endothelial damage, smooth muscle cell contraction resulting from spasmogenic substances generated during lyses of subarachnoid blood clots, changes in vascular responsiveness and inflammatory or immunological reactions of the vascular wall.A great deal of experimental and clinical research has been conducted in an effort to find ways to prevent these complications. However, to date, the main therapeutic interventions remain elusive and are limited to the manipulation of systemic blood pressure, alteration of blood volume or viscosity, and control of arterial dioxide tension.Even though no single pharmacological agent or treatment protocol has been identified which could prevent or reverse these deadly complications, a number of promising drugs have been investigated. Among these is the hormone erythropoietin (EPO), the main regulator of erythropoiesis. It has recently been found that EPO produces a neuroprotective action during experimental SAH when its recombinant form (rHuEPO) is systemically administered.This topic review collects the relevant literature on the main investigative therapies for cerebrovascular dysfunction after aneurysmal SAH. In addition, it points out rHuEPO, which may hold promise in future clinical trials to prevent the occurrence of vasospasm and cerebral ischemia after SAH.     

厄贝沙坦治疗缺血性心肌病临床评价

目的:评价厄贝沙坦治疗缺血性心肌病心力衰竭的临床疗效。方法:缺血性心肌病病人随机分为治疗组和对照组,其中治疗组22例(厄贝沙坦150mg,qd,PO,加常规处理),对照组20例(常规处理)。详细记录入院时和治疗4周临床症状体征、心脏彩超左室射血分数(LVEF)值及药物不良反应,观察治疗4周心功能恢复情况。结果:治疗组临床心功能改善程度较对照组大(P<0.01),治疗组LVEF改善较对照级更明显(P<0.01),两组均无咳嗽及其他显著不良反应发生。结论:厄贝沙坦能够明显改善缺血性心肌病患者心功能,可明显提高LVEF,不良反应少。